# Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

> **NCT05249959** · PHASE2 · RECRUITING · sponsor: **Fondazione Italiana Linfomi - ETS** · enrollment: 49 (estimated)

## Conditions studied

- Relapsed Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma

## Interventions

- **DRUG:** Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C))
- **DRUG:** Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)

## Key facts

- **NCT ID:** NCT05249959
- **Lead sponsor:** Fondazione Italiana Linfomi - ETS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-21
- **Primary completion:** 2026-03-21
- **Final completion:** 2029-03
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2026-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05249959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05249959, "Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05249959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*